Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4370595 | 0.98 | S1PR1 (0.40) | S1PR1S1PR3S1PR5S1PR4KCNK3 | |
| SCHEMBL4375455 | 0.94 | S1PR1 (0.41) | S1PR1S1PR3S1PR5S1PR4HTT | |
| SCHEMBL9155196 | 0.94 | S1PR1 (0.41) | S1PR1S1PR3S1PR5S1PR4HTT | |
| SCHEMBL28211526 | 0.89 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL4368176 | 0.83 | L3MBTL1 (0.42) | S1PR1S1PR3S1PR5CYP1A2HTT | |
| SCHEMBL9037919 | 0.83 | TSHR (0.44) | S1PR1S1PR3S1PR5S1PR4KCNK3 | |
| SCHEMBL7277972 | 0.82 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL7278231 | 0.82 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL856300 | 0.82 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL7027761 | 0.82 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-3959477-A | Methods of protection against emesis in mammals by administration of a heterocyclic benzamide | SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | S1PR1 4815/4885S1PR3 4725/4885S1PR5 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.